플라즈맵 Stock: price and insider trades · South Korea

플라즈맵 belongs to the Health Care sector. Filings by its managers are published through DART (FSS). Between 2 November 2025 and 2 November 2026, 3 insiders published 5 filings.

On the market, 2 insiders bought (2 purchases) while 2 insiders sold (3 sales). The totals exclude 5 filings filed without an amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. On the buying side, the filings list 1 chief executive among the declarants.

The last purchase on record was published on 19 June 2026, which is 144 days ago. Filings reach the DART (FSS) feed a median of 6 days after the trade. That lag is the time during which only the insider knows about the trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.

For context, the typical company on the same exchange (median of 2,655 companies) published 7 filings over the same period, against 5 filings here. Since 2022, the database holds 30 purchases and 9 sales by insiders of the company.

Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and UCB. These figures are compiled from regulatory filings published by DART (FSS). They describe what insiders did and are not a recommendation.